Sumitomo Pharma Co. Ltd
Sumitomo Pharma Co., Ltd. Manufactures, purchases, and sells pharmaceutical products for medical treatment in Japan, North America, and Asia. It offers therapeutic agents for parkinson's disease, type 2 diabetes, advanced prostate cancer, uterine fibroids and endometriosis, overactive bladder, and pediatric congenital athymia. The company also provides atypical antipsychotic, generic products, an… Read more
Sumitomo Pharma Co. Ltd (SMDPY) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of December 2025: 0.088x
Based on the latest financial reports, Sumitomo Pharma Co. Ltd (SMDPY) has a cash flow conversion efficiency ratio of 0.088x as of December 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($25.41 Billion) by net assets ($289.14 Billion). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Sumitomo Pharma Co. Ltd - Cash Flow Conversion Efficiency Trend (2005–2025)
This chart illustrates how Sumitomo Pharma Co. Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Sumitomo Pharma Co. Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Sumitomo Pharma Co. Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Qinchuan Machine Tool & Tool Group Share Co Ltd
SHE:000837
|
0.017x |
|
AIMA Technology Group Co Ltd
SHG:603529
|
0.301x |
|
Nos SGPS SA
LSE:0J1Z
|
0.165x |
|
Bright Smart Securities & Commodities Group Limited
F:0BX
|
-0.011x |
|
Altarea
LSE:0IRK
|
-0.029x |
|
ZHEJIANG ASIA-PACIFIC MECHANICAL & ELECTRONIC CO LTD
SHE:002284
|
0.066x |
|
United Parks & Resorts Inc
NYSE:PRKS
|
-0.307x |
|
ARS Pharmaceuticals, Inc
NASDAQ:SPRY
|
-0.319x |
Annual Cash Flow Conversion Efficiency for Sumitomo Pharma Co. Ltd (2005–2025)
The table below shows the annual cash flow conversion efficiency of Sumitomo Pharma Co. Ltd from 2005 to 2025.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-03-31 | $169.48 Billion | $16.50 Billion | 0.097x | +106.28% |
| 2024-03-31 | $156.14 Billion | $-241.89 Billion | -1.549x | -5379.43% |
| 2023-03-31 | $406.78 Billion | $11.94 Billion | 0.029x | -36.73% |
| 2022-03-31 | $673.57 Billion | $31.24 Billion | 0.046x | -77.83% |
| 2021-03-31 | $648.18 Billion | $135.60 Billion | 0.209x | +186.68% |
| 2020-03-31 | $632.11 Billion | $46.13 Billion | 0.073x | -25.37% |
| 2019-03-31 | $498.14 Billion | $48.71 Billion | 0.098x | -52.61% |
| 2018-03-31 | $452.72 Billion | $93.42 Billion | 0.206x | +339.59% |
| 2017-03-31 | $460.66 Billion | $21.62 Billion | 0.047x | -57.59% |
| 2016-03-31 | $446.47 Billion | $49.41 Billion | 0.111x | +65.01% |
| 2015-03-31 | $451.02 Billion | $30.25 Billion | 0.067x | -46.48% |
| 2014-03-31 | $398.54 Billion | $49.94 Billion | 0.125x | -12.32% |
| 2013-03-31 | $349.25 Billion | $49.91 Billion | 0.143x | -5.70% |
| 2012-03-31 | $319.23 Billion | $48.38 Billion | 0.152x | -10.79% |
| 2011-03-31 | $323.98 Billion | $55.04 Billion | 0.170x | +118.70% |
| 2010-03-31 | $343.48 Billion | $26.68 Billion | 0.078x | -4.14% |
| 2009-03-31 | $324.50 Billion | $26.30 Billion | 0.081x | -20.64% |
| 2008-03-31 | $318.36 Billion | $32.51 Billion | 0.102x | -17.49% |
| 2007-03-31 | $306.01 Billion | $37.87 Billion | 0.124x | +293.19% |
| 2006-03-31 | $288.63 Billion | $9.09 Billion | 0.031x | -72.54% |
| 2005-03-31 | $135.43 Billion | $15.52 Billion | 0.115x | -- |